Last month, DEA’s Diversion Control Division signed an immediate suspension order (ISO) against Aspire RX in Philadelphia, Pennsylvania. The ISO alleges the pharmacy failed to account for more than 47,000 controlled substance tablets during an accountability audit (including 33,600 oxycodone 30 mg tablets, 4,981 oxycodone 15 mg tablets, 8,780 alprazolam tablets, and 169 promethazine with codeine bottles). DEA may issue an ISO and suspend a registration in cases where there is “imminent danger to the public health or safety.” 21 U.S.C. 824(d).

In April, the DEA charged two ISOs and 13 Orders to Show Cause (OTSC).

Read more on administrative actions.